Genome Editing · Antibody Engineering · Cell Therapy

Alessio D. NahmadPhD

Pioneer in B Cell Engineering & Cell Therapy Scientist

An internationally recognized expert across genome editing, antibody engineering, and immune cell therapy. Alessio Nahmad helps research groups, biotechnology companies, and non-profits design, de-risk, and translate next-generation therapeutic workflows. He brings the perspective of a highly accomplished drug developer, scientist and a multi-time biotech co-founder.

Request a Consultation Consult Areas
Portrait of Alessio D. Nahmad, PhD
01About

A new class of therapy, built from the immune system up

Alessio D. Nahmad, PhD, is a scientist working at the frontier of genome editing, antibody engineering, and immune cell therapy. His research established foundational work in two areas: in vivo B cell engineering to produce broadly neutralizing antibodies — a proof of concept for a new class of "evolving drug" therapies — and CRISPR-Cas9 genome-editing safety, characterizing the aneuploidy and chromosomal truncations that arise in edited human T cells.

His works were published several times in high-impact peer-reviewed literature including multiple articles in Nature Biotechnology and Nature Communications, and he is a multiple time inventor including innovative cell therapeutics applications such as B cell engineering.

He received the ASGCT Excellence in Research Award (2021), presenting in the Presidential Symposium at the ASGCT Annual Meeting, and the ESGCT Early Career Investigator Award (2023).

A co-founder of multiple biotechnology ventures, including Tabby Therapeutics, he leads a research group at the Samueli Integrative Cancer Pioneering Institute and advises academic, industry, and non-profit partners on cell and gene therapy programs.

02Expertise

Where deep technical knowledge meets translation

B Cells

B & Plasma Cell Engineering

Ex vivo and in vivo engineering of B cells into durable, antibody-secreting "living drugs."

Antibodies

Antibody Engineering

IgH-locus editing, custom and heavy-chain-only antibodies, and native B cell antibody maturation.

CRISPR

Genome Editing & Safety

Editing strategy and safety review — off-target analysis and structural-variant / aneuploidy risk.

Delivery

AAV & Delivery

Vector design for in vivo delivery, including cell-type-specific expression strategies.

Translation

Cell Therapy Translation

Moving programs from preclinical proof-of-concept toward first-in-human studies.

Strategy

Early-Stage Biotech

Platform and company strategy from a multi-time co-founder, plus investor due diligence.

03Milestones & Recognition

Selected milestones

2026 · PatentInventor on animal-free cell-culture supplements patent — "Patient-Derived Effusions (PADE) and Patient-Derived Samples (PDS) as Protein-Rich, Animal-Free Cell Culture Supplements and Methods of Manufacture and Use" (Mor Applications at Rabin Medical Center) — scalable, low-cost and ethically sourced cell-culture supplements designed to replace fetal bovine serum (FBS) and human serum in cell therapy manufacturing.
2026 · Milestone500 cumulative citations — Alessio's peer-reviewed publications cross the 500-citation mark.
2025 · Peer-Reviewed PublicationsTwo new B cell engineering studies — engineered human B cells targeting tumor-associated antigens, and mouse B cells delivering an anti-HPV antibody. The Tabby Therapeutics teams demonstrated for the first time that engineered B cells can both present tumor antigens and elicit anti-tumor T-cell responses, opening the platform to solid-tumor immunotherapy.
2025 · ActivitiesJoins Winning Duchenne, a non-profit organization — Alessio will serve as a Scientific Advisor to the foundation developing a novel antibody-oligo conjugate therapy for Duchenne Muscular Dystrophy.
2025 · PatentInventor on multi-epitope anti-tumor antibody patent — PCT/IL2026/050047 — "Oncologic Multi-epitope General Antibodies" (Mor Applications at Rabin Medical Center) — collection, engineering and manufacturing of patient-derived polyclonal anti-tumor antibodies. This includes the core patent application for the first polyclonal patient-derived antibody therapeutic, polyclonal T-cell Engager (TCE) and polyclonal Antibody Drug Conjugates (ADC).
2024 · ActivitiesJoins the Scientific Advisors of Tabby Therapeutics — as a scientific co-founder, Alessio will provide strong value to the multiple cancer-focused pipelines of Tabby Therapeutics.
2024 · ActivitiesJoins The Samueli Integrative Cancer Pioneering Institute as Director of Research — Alessio will lead a team of professional scientists at the Rabin Medical Center to invent, research and develop novel therapeutics for cancer.
2024 · MilestoneAneuploidy paper exceeds 200 citations; i10-index reaches 6 — the CRISPR–Cas9 aneuploidy safety study (Nature Biotechnology) crosses the 200-citation mark, and six peer-reviewed papers each surpass 10 citations.
2023 · AwardFinalist, Falling Walls Science Summit — Tabby Therapeutics, a company co-founded by Alessio D. Nahmad, selected as a finalist in Berlin for engineered B cell therapies targeting solid tumors.
2023 · PatentCo-inventor on in vivo T cell engineering patent — WO2023187779A1 — "Site-specific in vivo T cell engineering, systems, compositions and methods thereof", co-invented with Dr. Barzel and Dr. Reuveni (Ramot at Tel-Aviv University) — extends the in vivo cell engineering platform from B cells to T cells.
2023 · AwardEarly Career Investigator Award — Alessio received the European Society of Gene and Cell Therapy (ESGCT) Early Career Investigator Award, recognized at the Annual Congress for research impact across antibody engineering and immune cell therapy.
2022 · International PressGlobal coverage of the CRISPR aneuploidy safety study — findings on chromosomal abnormalities in CRISPR–Cas9-edited T cells covered by BioCentury, The Scientist, ScienceDaily and other outlets as a key safety consideration for clinical cell-therapy protocols.
2022 · Peer-Reviewed PublicationHigh impact paper — Nature Biotechnology — Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage. In a study led by Alessio, the team provided the first systematic identification of frequent on-target aneuploidy and chromosomal truncations following CRISPR–Cas9 editing in primary human T cells, reframing safety standards for the engineered cell-therapy field.
2022 · Peer-Reviewed PublicationNew study — MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression. In a study led by Sabina Pozzi in the Satchi-Fainaro lab, the team showed for the first time that MCP-1/CCR2 axis blockade can re-sensitize the brain microenvironment against melanoma metastatic progression.
2022 · International PressGlobal coverage of HIV B cell engineering — research highlighted in a Nature editorial commentary and featured by The Independent, NoCamels, Rotary International and additional broad-media outlets as a potential single-injection HIV approach.
2022 · Peer-Reviewed PublicationHigh impact paper — Nature Biotechnology — In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. In a study led by Alessio, the team reported the first demonstration of site-specific in vivo engineering of lymphocytes.
2021 · Company FormationCo-founded Tabby Therapeutics — Tel Aviv University / Arkin Bio venture translating engineered B cell therapies toward solid-tumor immunotherapy (Ness Ziona, IL · Boston, MA, USA).
2021 · AwardExcellence in Research Award — Alessio received the American Society of Gene and Cell Therapy (ASGCT) Excellence in Research Award; his abstract was selected for the Presidential Symposium at the Annual Meeting.
2020 · PatentInventor on core B cell engineering patent — WO2020053865A1 — "Genetic engineering of B cell receptors and uses thereof in antigen-induced antibody secretion" (Ramot at Tel-Aviv University) — covers ex vivo and in vivo editing approaches that anchor the platform.
2020 · Peer-Reviewed PublicationHigh impact paper — Nature Communications — Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. In a study led by Alessio, the team provided foundational proof that ex vivo–engineered B cells can retain immunological memory, undergo isotype switching and clonally expand in vivo, establishing engineered B cells as a self-improving, evolving drug.
2020 · Peer-Reviewed PublicationHigh impact paper — Nucleic Acids Research — Bacteriophage Integrase-mediated RMCE established as a candidate platform for human gene therapy. In a study led by Amer Elias in the Kolot lab, the team provided the first demonstration of Integrase-mediated recombinase-mediated cassette exchange as a precise, site-specific genome-engineering tool for human gene therapy.

Full record: Google Patents · Google Scholar

04Collaboration & Consulting

Three ways to collaborate

From senior scientific guidance to hands-on research partnership, engagements are tailored to where a program is and who is running it.

Academia

Research Collaboration

ADN Labs logo

Joint projects in partnership with Alessio's laboratory (ADN Labs) at the Samueli Integrative Cancer Pioneering Institute — co-developing antibody, B cell, and genome-editing approaches.

Industry

Programs & Consultancy

ADN Labs logo Alessio David Nahmad, PhD logo Alessio David Nahmad, PhD

Sponsored research collaboration programs and scientific consultancy for biotech and pharma — platform strategy, experimental design, editing safety, and early-stage company guidance from a multi-time co-founder.

Non-profit

Scientific Consultancy

Alessio David Nahmad, PhD logo Alessio David Nahmad, PhD

Advisory support for foundations and non-profit research organizations advancing immunotherapy and gene therapy.

Areas of Engagement
  • Scientific advisory for cell & gene therapy programs
  • Experimental design & feasibility for B cell / antibody engineering
  • Genome-editing strategy & safety review (off-target, structural variants, aneuploidy)
  • AAV / delivery design for in vivo approaches
  • Preclinical-to-clinical translational guidance
  • Early-stage biotech strategy & technical due diligence for investors
05FAQ

Common questions

What does Alessio D. Nahmad specialize in?

Genome editing, antibody engineering, and immune cell therapy. He is a pioneer in B cell engineering and a recognized voice on CRISPR genome-editing safety, with expertise spanning in vivo and ex vivo cell engineering, AAV vector design, and early-stage biotech strategy.

Is he available for consulting?

Yes. He advises cell and gene therapy programs on experimental design, antibody and B cell engineering workflows, genome-editing strategy and safety, and preclinical-to-clinical translation, and supports investor due diligence in immunotherapy.

What kinds of organizations does he work with?

Early- and growth-stage biotech companies, academic and clinical research groups, and venture investors evaluating immunotherapy and gene-editing opportunities.

06Contact

Start a conversation

For consulting inquiries, research collaborations, or speaking engagements, Alessio can be reached directly.

Also on LinkedIn.